Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immuron Limited ( (AU:IMC) ) has provided an update.
Immuron Limited announced a change in its share registry management services, transitioning from Automic Group to Boardroom Pty Limited effective December 8, 2025. This strategic move is expected to streamline the company’s administrative processes, potentially enhancing operational efficiency and stakeholder relations.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company that specializes in developing and commercializing orally delivered targeted polyclonal antibodies for treating infectious diseases. The company is known for its product Travelan®, which is designed to reduce the risk of travelers’ diarrhea by using hyperimmune bovine antibodies to prevent colonization by diarrhea-causing bacteria.
Average Trading Volume: 573,162
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$18.34M
For a thorough assessment of IMC stock, go to TipRanks’ Stock Analysis page.